Author: Elizabeth Linderbaum

Health Care News, Health Center Advocacy, Health Center Federal Policy, Health Center Regulatory Issues, Uncategorized

Defending the 340B Program from Every Direction

The 340B Drug Pricing Program has weathered attacks from different health care actors for years. Just months after the outbreak of the COVID-19 pandemic, manufacturers launched attacks by refusing to sell 340B-priced drugs to health centers that use contract pharmacies to increase patient access. This combination of manufacturer restrictions, alongside existing discriminatory contracting actions taken …